(Q38151250)

29 August 2017

0 references

BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis (English)

1 reference

29 August 2017

1 reference

1 reference

1 reference

1 reference

C Clancy

1

1 reference

29 August 2017

J P Burke

series ordinal

2

1 reference

29 August 2017

M F Kalady

series ordinal

3

1 reference

29 August 2017

J C Coffey

series ordinal

4

1 reference

29 August 2017

publication date

1 December 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

15

1 reference

29 August 2017

issue

12

1 reference

29 August 2017

page(s)

e711-8

1 reference

BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Role of the serrated pathway in colorectal cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Is BRAF mutation associated with interval colorectal cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

A road map for efficient and reliable human genome epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FCODI.12427

21 January 2018

Identifiers

DOI

10.1111/CODI.12427

1 reference

29 August 2017

1 reference